Rank #1014BBIO

BridgeBio Pharma, Inc.

$70.72

-4.34% (Daily)

Market Cap

$13.55B

Revenue

$353.78M

Rank by MCap

#1014

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Neil Kumar Ph.D.

Headquarters

Palo Alto, CA

Employees

725

About BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 d...